Triple

T22457979
Position Surface form Disambiguated ID Type / Status
Subject Swissmedic E555161 entity
Predicate cooperatesWith P435 FINISHED
Object Pharmaceutical Inspection Co-operation Scheme — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmaceutical Inspection Co-operation Scheme | Statement: [Swissmedic, cooperatesWith, Pharmaceutical Inspection Co-operation Scheme]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Pharmaceutical Inspection Co-operation Scheme
Context triple: [Swissmedic, cooperatesWith, Pharmaceutical Inspection Co-operation Scheme]
  • A. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • B. European Federation of Pharmaceutical Industries and Associations
    The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association representing the research-based pharmaceutical industry in Europe, advocating for policies that support innovation, patient access to medicines, and a competitive life sciences sector.
  • C. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • D. International Pharmaceutical Federation
    The International Pharmaceutical Federation is a global federation representing pharmacists and pharmaceutical scientists, working to advance pharmacy practice, science, and education worldwide.
  • E. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Pharmaceutical Inspection Co-operation Scheme
Target entity description: The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is an international organization that harmonizes Good Manufacturing Practice (GMP) standards and facilitates cooperation among pharmaceutical regulatory authorities worldwide to ensure the quality and safety of medicines.
  • A. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
    The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
  • B. European Federation of Pharmaceutical Industries and Associations
    The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association representing the research-based pharmaceutical industry in Europe, advocating for policies that support innovation, patient access to medicines, and a competitive life sciences sector.
  • C. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • D. International Pharmaceutical Federation
    The International Pharmaceutical Federation is a global federation representing pharmacists and pharmaceutical scientists, working to advance pharmacy practice, science, and education worldwide.
  • E. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e51fdec8190adfdf9f8a6362221 completed April 16, 2026, 5:37 p.m.
NER Named-entity recognition batch_69f15b7d00208190955a70e2c22d25a4 completed April 29, 2026, 1:14 a.m.
Created at: April 16, 2026, 8:48 p.m.